Pygeum is one of the few prostate botanicals with evidence focused specifically on nighttime urination. It also carries a sourcing and sustainability concern that many product pages leave out.
By Dr. Marcus Reed, MD · Last Updated: July 23, 2026
Pygeum africanum, now classified as Prunus africana, is a bark extract from the African plum tree and has been used in European urology since the 1960s. A meta-analysis of 18 randomized trials found that men taking pygeum were more than twice as likely to report improved urinary symptoms. The review reported an approximate 19% reduction in nocturia, a 24% reduction in residual urine volume, and a 23% increase in peak urine flow compared with placebo. Typical studied doses range from 100–200 mg daily of an extract standardized to 14% triterpenes.
Budget prostate formulas often leave out pygeum, while more comprehensive blends frequently include it. The ingredient has decades of medical use in parts of Europe and a notable meta-analysis behind it. Its strongest evidence relates to nighttime urination, the symptom many men find most disruptive. Buyers should also understand the sustainability concerns tied to harvesting bark from Prunus africana trees.
Prunus africana, historically classified as Pygeum africanum, is an evergreen tree native to the montane forests of tropical Africa, growing across Cameroon, Kenya, Madagascar, Uganda, and neighboring regions. It can reach 40 metres in height and is sometimes called the African plum or African cherry.
The medicinal part is the bark. Traditional healers across sub-Saharan Africa used bark preparations for urinary complaints and what was described as "old man's disease" long before any European involvement. In the 1960s French researchers investigated it, and a standardized lipophilic bark extract was subsequently developed and registered as a pharmaceutical product in France and Italy, where it has been prescribed for BPH ever since.
The extract contains three groups of lipid-soluble active constituents: phytosterols (principally beta-sitosterol), pentacyclic triterpenoids (including ursolic and oleanolic acids), and ferulic esters of fatty alcohols (notably n-docosanol). Standardisation is normally to 12-14% total sterols and triterpenes.
Pygeum's mechanism is meaningfully different from saw palmetto's, which is the reason the two are complementary rather than redundant.
The pentacyclic triterpenoids are effective anti-oedema agents, and the phytosterol fraction—particularly beta-sitosterol—reduces elevated prostaglandin levels found in men with BPH. Reduced prostaglandin activity means reduced inflammation and reduced tissue swelling, which relieves pressure on the urethra without needing to alter the gland's cell count.
Pygeum extract has been shown to inhibit fibroblast growth factors including bFGF and EGF, which are implicated in the fibrous and stromal proliferation component of prostate enlargement. This is a distinct target from the androgen pathway that saw palmetto and beta-sitosterol act on.
Some research indicates pygeum improves bladder contractility and elasticity independently of prostate effects. Since long-standing obstruction causes secondary bladder wall changes that persist even when obstruction is relieved, an ingredient acting on the bladder itself is useful—and may explain why its nocturia evidence is comparatively strong.
Laboratory work has found ethanolic pygeum extracts inhibit the growth of prostate cell lines, induce apoptosis, and alter cell kinetics, with investigators concluding it has a significant role in regulating prostate cancer processes in vitro and in animal models (PMID 17709901). This is preclinical evidence about mechanism, not a claim that pygeum treats or prevents cancer in humans, and it should not be read that way.
Pygeum's headline evidence is a systematic review and quantitative meta-analysis published in the American Journal of Medicine, which pooled 18 randomized controlled trials involving over 1,500 men. Seventeen of the 18 were double-blinded, with a mean study duration of 64 days (PMID 11099686).
The reviewers themselves were careful about the quality of the underlying evidence. Many studies did not report results in a form permitting meta-analysis. Only one of the 18 reported a method of treatment allocation concealment—a significant methodological gap. The studies were relatively short, averaging around two months, and mostly conducted decades ago under different standards. Modern large-scale placebo-controlled trials of pygeum are notably scarce.
So the fair reading is: consistent and reasonably large effects across a substantial number of trials, tempered by methodological limitations typical of the era. That is a stronger evidence base than most supplement ingredients have, and weaker than a modern pharmaceutical approval package.
A randomized double-blind study comparing once-daily and twice-daily dosing found both effective with a long-term open label extension, supporting practical once-daily use. Pygeum also appears in the broader nutraceutical literature for BPH alongside Serenoa repens, lycopene, and zinc (PMID 31577095).
Standard dosing is 100mg daily of extract standardized to approximately 14% triterpenes and 0.5% n-docosanol, though 50mg twice daily and 200mg daily have both been used. Some protocols recommend cycling—six to eight weeks on, then a break—though continuous use is also common.
In combination formulas such as ProstaStream, pygeum appears alongside saw palmetto and a plant sterol complex. Because it targets inflammation and growth factors rather than the androgen pathway, its inclusion adds mechanistic coverage rather than duplicating what is already there—which is why its presence is a reasonable marker of a thoughtfully constructed formula.
This deserves its own section because it is a real issue and most supplement content omits it entirely.
Harvesting pygeum requires stripping bark from the tree. Done properly—removing bark from opposite quarters of the trunk and allowing regeneration—the tree survives and can be re-harvested years later. Done improperly, through complete ring-barking, the tree dies.
Commercial demand from Europe and North America drove exactly the improper kind of harvesting across parts of Africa for decades. Prunus africana was consequently listed under CITES Appendix II, meaning international trade is regulated and requires permits confirming sustainable sourcing. Some exporting countries have faced trade suspensions over unsustainable practices.
The practical implication for buyers: sustainably sourced pygeum exists, from managed plantations and certified wild-harvest programmes, but it costs more. Very cheap pygeum is a reasonable prompt to ask where it came from. Some manufacturers state their sourcing; most do not. If this matters to you, it is worth contacting the manufacturer directly, and it is a legitimate reason some formulas use pygeum sparingly.
Pygeum's tolerability in trials was good, with adverse effect rates comparable to placebo across the meta-analysed studies.
Pygeum's distinctive value is its evidence profile on nocturia specifically. For a man whose main complaint is waking two or three times a night, that is the most relevant outcome measure available, and pygeum's meta-analysis addresses it directly with a 19% reduction figure.
It works best as part of a combination rather than alone, because its mechanism sits alongside rather than overlapping the androgen-pathway ingredients. A formula containing beta-sitosterol, standardized saw palmetto, and pygeum covers hormonal, inflammatory, and growth-factor pathways—which is a coherent design rather than ingredient-stuffing.
Pair it with the behavioral measures that address nocturia directly: fluid timing, evening alcohol reduction, early-evening leg elevation, and double voiding. Our nocturia guide covers these in detail. Supplements and behavior together consistently outperform either alone.
And keep the limits in view. Two months of pygeum will not resolve severe obstruction, and any sudden change in urinary pattern, blood in the urine, or inability to urinate needs a doctor rather than a capsule.
One thing distinguishes pygeum from almost every other ingredient in the prostate aisle: in several countries it is not a supplement at all.
Standardized pygeum bark extract has been registered and prescribed as a pharmaceutical medicine in France and Italy for the management of BPH since the 1970s, and has been available as a registered product in other European and African markets. In the United States and United Kingdom it is sold as a dietary supplement, subject to entirely different regulatory requirements.
This matters for how you interpret the evidence. Much of the trial literature was generated in a European pharmaceutical context, testing a specific standardized preparation under medicine-development conditions, rather than testing whatever happened to be in a supplement bottle. That is part of why pygeum's trial record is more internally consistent than saw palmetto's—the material being tested was more consistent.
It also means a European registered product and an American supplement labeled "pygeum" may differ considerably. When a study reports a benefit at 100mg, it is reporting a benefit for a defined extract, not for 100mg of any bark preparation. The standardisation figure on the label is the only bridge between the two, which is why its absence is so significant.
A related practical point: because it is a prescription medicine elsewhere, some clinicians outside those countries are more familiar with pygeum than with typical supplement ingredients. It is worth raising by name rather than describing it vaguely as "a herbal thing for my prostate".
Pygeum is rarely used alone, and the combinations have some logic behind them.
The most common pairing, and a complementary one. Saw palmetto works predominantly on the androgen pathway; pygeum on inflammation, growth factors, and bladder function. Historical comparative work has placed the two side by side, and combination products have been standard in European practice for decades. Where one addresses the hormonal driver of tissue growth, the other addresses the swelling and bladder dysfunction that translate that growth into symptoms.
Partly overlapping, since pygeum itself contains phytosterols including beta-sitosterol. Adding a separate plant sterol complex increases the total sterol dose toward the 60-130mg range shown effective in trials, which pygeum alone at 100mg would not reach. This is a reasonable design rather than duplication.
A traditional European combination, with the nettle-plus-saw-palmetto pairing having more supporting evidence than nettle alone. Pygeum, nettle, and saw palmetto together appear in several long-standing formulations.
This requires a conversation, not a decision made alone. Men already taking an alpha-blocker or 5-alpha-reductase inhibitor should not simply add botanicals—particularly given pygeum's status as a medicine in some jurisdictions and the PSA-interpretation issue. There is no reason to assume harm, but there is every reason to have your prescriber know the full picture.
For men not yet on prescription treatment, a combination formula such as ProstaStream containing pygeum alongside saw palmetto and plant sterols represents a coherent first step for mild-to-moderate symptoms—provided it is a first step, with a twelve-week evaluation window and a plan to escalate if nothing changes, rather than an indefinite substitute for finding out what is going on.
Key takeaway: Pygeum has the strongest specific evidence of any natural ingredient for nocturia—a 19% reduction across an 18-trial meta-analysis—and works through anti-inflammatory and growth-factor pathways rather than the androgen route, making it complementary to saw palmetto. Look for 100-200mg standardized to 14% triterpenes, and be aware of the CITES sustainability issue.
A 15-ingredient prostate formula built around saw palmetto, beta-sitosterol, and pygeum, backed by a 60-day money-back guarantee.
Order from Official Website